Checkpoint Inhibitors, Palliative Care, or Hospice

Area of Science:

• Oncology
• Palliative Care
• Immunotherapy

Background:

• Checkpoint inhibitors (CTLA-4, PD-1, PD-L1) have transformed oncology, yet only a subset of patients achieve long-term responses.
• Most patients do not respond to these therapies, even with favorable biomarkers like PD-L1.

Purpose of the Study:

• To contextualize checkpoint inhibitor trials within palliative care.
• To discuss the impact of these therapies on patient-related outcomes and end-of-life care.

Main Methods:

• Review of pivotal studies on checkpoint inhibitor efficacy and safety.
• Analysis of available data on quality of life and symptom response.

Main Results:

• Limited data exists on quality of life and symptom responses.
• Life extension averages 2-3 months, with long-term responses in a minority.
• High cost-effectiveness ratios (81,000-200,000 USD per quality-adjusted life-year saved).
• Adverse effects are often suboptimally reported.
• Meaningful response rates are modest by ESMO criteria.

Conclusions:

• Checkpoint inhibitors are primarily palliative for advanced cancers.
• Integration of palliative care specialists is essential for symptom assessment and advanced care planning.
• Understanding treatment-related autoimmune toxicities is critical for oncologists and palliative specialists.
• The impact of checkpoint inhibitors on end-of-life care utilization and costs remains undetermined.